Drugs / Aliskiren
Aliskiren
also known as
SPP100 · Tekturna · Rasilez · ALISKIREN FUMARATE · Aliskiren fumarate component of amturnide aliskiren hemifumarate · Aliskiren fumarate component of raprazo-hct aliskiren hemifumarate · Aliskiren fumarate component of rasilamlo aliskiren hemifumarate · Aliskiren fumarate component of rasilez-hct aliskiren hemifumarate · +18 more
Small molecule targets REN via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Rasilez | — | 2007-08-22 | europa.eu ↗ |
| Approved | US (FDA) | TEKTURNA | — | 2007-03-05 | fda.gov ↗ |
Trials 123 · started per year
today
US approved 2007
EU approved 2007
1
7
19
12
7
21
25
20
6
2
1
1
1
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01568775 | Jun → Sep 2010 | end stage renal failure | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00424541 | Jan → Aug 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00416728 | Nov 2006 → ? | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00416468 | Nov 2006 → ? | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT00834041 | Apr 2009 → Jan 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 1/2 | NCT00464776 | Oct 2005 → Apr 2008 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 1/2 | NCT00464880 | Sep 2005 → Nov 2007 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 1/2 | NCT00461136 | Aug 2005 → Nov 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT04183101 | Oct 2020 → Dec 2029 expected | C3 glomerulonephritis, dense deposit disease, membranoproliferative glomerulonephritis | Region Skane | Recruiting | No outcome recorded |
| Phase 2 | NCT01480791 | Jan 2012 → Dec 2013 | diabetes mellitus, hypertensive disorder | Sir Mortimer B. Davis - Jewish General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01302899 | Jan → Dec 2011 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01125514 | May 2010 → Aug 2011 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01080768 | Feb → Nov 2010 | hypertensive disorder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00939588 | Jul → Dec 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00923156 | May 2009 → Feb 2011 | systolic heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00819767 | Feb → Oct 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00768040 | Sep 2008 → Feb 2011 | diabetic macular edema | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00417170 | Oct 2007 → Jul 2010 | hypertensive disorder, metabolic syndrome X | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00498433 | Jun 2007 → Mar 2012 | abdominal obesity-metabolic syndrome, hypertensive disorder | Novartis | Terminated | No outcome recorded |
| Phase 2 | NCT00409578 | Feb 2007 → Apr 2009 | acute coronary syndrome | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00246584 | Oct 2004 → ? | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00097955 | Oct 2004 → Apr 2007 | diabetic kidney disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00311012 | Aug 2004 → Mar 2005 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 350 trials | ||||||
| Phase 3 | NCT01237873 | Jan 2011 → Feb 2012 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01259297 | Jan 2011 → Nov 2012 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01151410 | Aug 2010 → Aug 2015 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01715207 | Jun 2010 → Oct 2014 | Marfan syndrome | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01150357 | Jun 2010 → Aug 2014 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01113047 | May → Oct 2010 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00894387 | May 2009 → Aug 2012 | congestive heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00870493 | Apr 2009 → Mar 2012 | IgA glomerulonephritis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00853827 | Mar 2009 → Jan 2013 | coronary atherosclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00853658 | Mar 2009 → Oct 2015 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00867490 | Mar → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00841672 | Jan → Sep 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00797862 | Nov 2008 → Nov 2010 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00778921 | Oct 2008 → Jun 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00765674 | Sep 2008 → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00739973 | Sep 2008 → May 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00667719 | Jun 2008 → Oct 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00706134 | May 2008 → Apr 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00549757 | Oct 2007 → Feb 2013 | cardiovascular disorder, type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00529451 | Sep 2007 → Jul 2008 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00414609 | Dec 2006 → Sep 2009 | myocardial infarction | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00402103 | Nov 2006 → Apr 2008 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00387517 | Oct 2006 → Aug 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00386607 | Oct 2006 → Jul 2008 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00386139 | Sep 2006 → Jul 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00368277 | Sep 2006 → Feb 2008 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00344110 | Jun 2006 → Apr 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00343551 | May 2006 → Jan 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00299806 | Apr → Nov 2006 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00299832 | Apr 2006 → May 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00262236 | Nov 2005 → Aug 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00260923 | Nov 2005 → Nov 2006 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219141 | Oct 2005 → Nov 2007 | essential hypertension, heart disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00518765 | Oct 2005 → Aug 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219193 | Oct 2005 → Jan 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171405 | Jun 2005 → Feb 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219180 | Jun 2005 → Sep 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219102 | Jun 2005 → May 2007 | diabetes mellitus, essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219011 | May 2005 → Feb 2007 | heart failure | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219167 | Apr 2005 → Feb 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219154 | Mar 2005 → Jan 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00294710 | Mar 2005 → Jul 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219076 | Feb → Oct 2005 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219050 | Feb → Nov 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219063 | Feb 2005 → Mar 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219115 | Jan 2005 → Mar 2006 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219089 | Nov 2004 → Aug 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219128 | Nov 2004 → Jun 2005 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219024 | Aug 2004 → Jun 2005 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00219037 | Jun 2004 → Oct 2005 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 441 trials | ||||||
| Phase 4 | NCT01922141 | May 2015 → Jun 2018 | hypertensive disorder | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT01570686 | Apr → Nov 2012 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01368536 | May 2011 → Feb 2012 | hypertensive disorder, type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01235910 | May 2011 → Dec 2012 | hypertensive disorder | University of Colorado, Denver | Terminated | No outcome recorded |
| Phase 4 | NCT01138423 | Aug 2010 → Feb 2012 | hypertensive disorder, metabolic syndrome X | UMC Utrecht | Completed | No outcome recorded |
| Phase 4 | NCT01156207 | Jul 2010 → Jul 2013 | heart failure | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01176032 | Jun 2010 → Apr 2013 | hypertensive disorder, hypertensive heart disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01184599 | Jun 2010 → Mar 2013 | IgA glomerulonephritis, hypertensive disorder | Kagawa University | Unknown | No outcome recorded |
| Phase 4 | NCT01060865 | Mar 2010 → Oct 2011 | hypertensive disorder | Meir Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01095822 | Mar → Dec 2010 | diabetes mellitus | HeartDrug Research LLC | Unknown | No outcome recorded |
| Phase 4 | NCT01056731 | Feb 2010 → Oct 2011 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01635387 | Feb 2010 → Sep 2012 | end stage renal failure, essential hypertension | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT01040494 | Jan → Jul 2010 | congestive heart failure | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01070030 | Jan → Oct 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01038895 | Nov 2009 → Mar 2010 | hypertensive disorder, type 2 diabetes mellitus | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT01048047 | Nov → Dec 2009 | hypertensive disorder | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT01042392 | Nov 2009 → Jan 2011 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01394770 | Sep 2009 → Sep 2012 | hypertensive disorder | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT00994253 | Aug 2009 → Dec 2012 | hypertensive disorder, type 2 diabetes mellitus | Corewell Health East | Withdrawn | No outcome recorded |
| Phase 4 | NCT01150201 | Jul 2009 → Aug 2014 | kidney disorder | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT00922311 | Jul 2009 → Dec 2010 | IgA glomerulonephritis | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT03115853 | Jun 2009 → Jan 2012 | hypertensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00942994 | Jun 2009 → Mar 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00927394 | May 2009 → Oct 2011 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00865020 | Mar 2009 → Jun 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01219413 | Mar 2009 → Jul 2010 | chronic kidney disease, proteinuria | Medical University of Gdansk | Completed | No outcome recorded |
| Phase 4 | NCT00853957 | Feb → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00809926 | Jan → Jul 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00797316 | Nov 2008 → Dec 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00787605 | Nov 2008 → Jan 2010 | diabetes mellitus, hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00760266 | Sep 2008 → Apr 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00765947 | Sep 2008 → Aug 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00772577 | Aug 2008 → Mar 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00739596 | Jul 2008 → Mar 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00719316 | Jul 2008 → Jul 2009 | chronic kidney disease, hypertensive disorder | UMC Utrecht | Unknown | No outcome recorded |
| Phase 4 | NCT00660309 | Apr 2008 → Dec 2009 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00654875 | Mar → Nov 2008 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00542269 | Mar 2008 → Jul 2009 | metabolic syndrome X | Novartis | Terminated | No outcome recorded |
| Phase 4 | NCT00631917 | Feb 2008 → Sep 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00818779 | Jan 2008 → Aug 2011 | coronary artery disorder, type 2 diabetes mellitus | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 4 | NCT00441064 | Jan → Nov 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT02446548 | Mar 2013 → Apr 2014 | proteinuria | Medical University of Gdansk | Completed | No outcome recorded |
| — | NCT01425242 | Sep 2011 → Dec 2013 | abdominal aortic aneurysm, essential hypertension | Amsterdam UMC, location VUmc | Terminated | No outcome recorded |
| — | NCT01093781 | Nov 2010 → Dec 2011 | idiopathic membranous glomerulonephritis | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT01298258 | Jul 2010 → Jul 2013 | heart failure | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT01252238 | Jun 2010 → Dec 2012 | — | Brigham and Women's Hospital | Terminated | No outcome recorded |
| — | NCT01165983 | Nov 2009 → Jan 2012 | type 2 diabetes mellitus | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT00627861 | Nov 2008 → May 2010 | hypertensive disorder | The Rogosin Institute | Terminated | No outcome recorded |
| — | NCT00732407 | Sep 2008 → Sep 2009 | atherosclerosis, type 2 diabetes mellitus | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 31 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01217736 Comparator | Sep 2010 → Nov 2011 | impaired renal function disease | Vitae Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01103245 Comparator | Mar 2010 → Jul 2012 | diabetes mellitus | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00856960 Comparator | Jan → Mar 2010 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00933920 Comparator | Jun → Dec 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00881439 Comparator | Apr 2009 → Jul 2012 | heart failure, kidney failure | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01417104 Comparator | Oct 2009 → Dec 2011 | atherosclerosis | Ohio State University | Terminated | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT02909166 Comparator | Jan 2012 → Dec 2016 | atrial fibrillation | Mika Lehto | Unknown | No outcome recorded |
| Phase 3 | NCT01237223 Comparator | Oct 2010 → May 2011 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01318395 Comparator | May 2010 → Jun 2013 | hypertensive disorder | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT01067326 Comparator | Feb 2010 → Dec 2011 | — | Mayo Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT00777946 Comparator | Oct 2008 → May 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00705575 Comparator | Jun 2008 → Apr 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT06718062 Comparator | May 2021 → May 2024 | essential hypertension | Hansung University | Completed | No outcome recorded |
| Phase 4 | NCT01893788 Comparator | Apr 2013 → Mar 2016 | hypertensive heart disease | Nagoya University | Unknown | No outcome recorded |
| Phase 4 | NCT01827202 Comparator | Dec 2012 → Feb 2016 | chronic kidney disease, hypertensive disorder, proteinuria | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01519635 Comparator | Oct 2011 → Oct 2014 | hypertensive disorder | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 4 | NCT01461499 Comparator | Oct 2011 → Aug 2014 | essential hypertension, type 2 diabetes mellitus | Shiga University | Completed | No outcome recorded |
| Phase 4 | NCT01472796 Comparator | Jul 2011 → Jul 2013 | hypertensive disorder | Wayne State University | Unknown | No outcome recorded |
| Phase 4 | NCT01349114 Comparator | Jun 2011 → Jan 2012 | diabetes mellitus, hypertensive disorder | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 4 | NCT01409408 Comparator | Apr 2011 → Apr 2013 | hypertensive disorder, type 2 diabetes mellitus | Hospital Universitario Pedro Ernesto | Withdrawn | No outcome recorded |
| Phase 4 | NCT01284114 Comparator | Feb 2011 → May 2012 | chronic kidney disease, essential hypertension | Jichi Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01305850 Comparator | Jul 2010 → Aug 2011 | — | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 4 | NCT01437943 Comparator | Apr 2010 → Jan 2012 | chronic renal failure syndrome | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01541267 Comparator | Dec 2009 → May 2011 | chronic kidney disease, proteinuria | Medical University of Gdansk | Completed | No outcome recorded |
| Phase 4 | NCT00949351 Comparator | Sep 2009 → Jul 2010 | type 2 diabetes mellitus | Lerdsin General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01129557 Comparator | Sep 2009 → Jan 2012 | IgA glomerulonephritis, diabetic kidney disease, focal segmental glomerulosclerosis, membranous glomerulonephritis +2 | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT00974922 Comparator | Aug 2009 → Dec 2011 | hypertensive disorder, vitamin D deficiency | UConn Health | Terminated | No outcome recorded |
| Phase 4 | NCT00961207 Comparator | Aug 2009 → Jul 2012 | diabetes mellitus, diabetic kidney disease, proteinuria | Cook County Health | Terminated | No outcome recorded |
| Phase 4 | NCT00982033 Comparator | Jul 2009 → Sep 2011 | heart failure | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00935064 Comparator | Jun 2009 → Oct 2011 | diabetes mellitus | Christiana Care Health Services | Completed | No outcome recorded |
| — | NCT00773084 Comparator | Sep 2008 → Aug 2009 | diastolic heart failure | Texas Tech University Health Sciences Center | Withdrawn | No outcome recorded |
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 158 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aliskiren | “antiproteinuric effect as well as that antihypertensive effect of aliskiren 300 mg / d versus ramipril 10 mg daily” NCT01038895 ↗152“Valturna (aliskiren 150 mg/valsartan 160 mg) tablet” NCT01368536 ↗ “Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg” NCT01237873 ↗ |
| Known as | ALISKIREN FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of amturnide aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of raprazo-hct aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of rasilamlo aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of rasilez-hct aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of rasitrio aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of sprimeo-hct aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of tekamlo aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of tekturna hct aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren fumarate component of valturna aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren hemifumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren hemifumarate component of amturnide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren hemifumarate component of tekamlo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskiren hemifumarate component of valturna | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskirene | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Aliskireno | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Enviage | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | NSC-759185 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Rasilez | “Aliskiren (Rasilez®) is a new antihypertensive drug” NCT01060865 ↗1“aliskiren (Rasilez 300 mg, Novartis Europharm” NCT01541267 ↗ |
| Known as | Riprazo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | SPP-100B | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | SPP100 | “We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18...” PMID 11799102 ↗ Jan 20025“A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction” NCT00299832 ↗ “Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension” NCT00344110 ↗ “SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension” NCT00299806 ↗ “SPP100 (aliskiren)” NCT00424541 ↗ |
| Known as | Sprimeo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗ |
| Known as | Tekturna | “This study will evaluate the effects of Vitamin D replacement and the effects of an approved medication for hypertension, aliskiren (Tekturna), in patients with high blood...” NCT00974922 ↗3“The purpose of this study is to assess the effect of Tekturna (aliskiren), in combination with an ACE and calcium channel blocker in hypertensive patients diagnosed with Type...” NCT00994253 ↗ “Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months” NCT01129557 ↗ “Aliskiren (Tekturna) is a recently FDA-approved potent direct renin inhibitor” NCT01095822 ↗ |
| Known as | Tekturna (aliskiren) | “Tekturna (aliskiren)” NCT01235910 ↗ |
| Known as | Tekturna (Aliskirin) | “Tekturna (Aliskirin)” NCT01472796 ↗ |
| Action | Inhibit | “aliskiren, an oral direct renin inhibitor” PMID 18525041 ↗ Jun 2008 |
| Modality | Small molecule | “Aliskiren is an orally active, non-peptide renin inhibitor.” NCT00627861 ↗ |
| Route | Oral | “aliskiren, an oral direct renin inhibitor” PMID 18525041 ↗ Jun 2008 |
| Target | REN | “the direct renin inhibitor aliskiren” PMID 21659626 ↗ Jun 2011 |